Core Viewpoint - The company is proactively reducing the price of its KHA130 blood perfusion device to 339 yuan starting from September 2025 to fulfill social responsibility and respond to market competition [1] Group 1: Pricing Strategy - The price reduction for the KHA130 blood perfusion device will be implemented across various provinces, with the specific timing dependent on local platforms [1] - The KHA130 accounted for 5.22% of the company's revenue in the first three quarters of 2025 [1] Group 2: Financial Impact - The price reduction initiative has not significantly affected the company's overall gross margin to date [1] - Future impacts on financial performance will depend on the effectiveness of market promotion efforts, with updates to be disclosed in regular reports [1]

Core Viewpoint - The company has reported a significant reduction in sales expenses and is adjusting the pricing of its blood perfusion device in response to new healthcare policies in China [1] Group 1: Sales Expenses - In the first half of 2025, the company's sales expenses amounted to 24.961 million yuan, representing a year-on-year decrease of 26.75% [1] Group 2: Policy Impact - The National Healthcare Security Administration issued a guideline in June this year, adding "blood dialysis perfusion fee" and "plasma adsorption fee" as new items, which have been officially included in the medical insurance projects with independent pricing standards [1] - Over twenty provinces in China are actively implementing these policies, which are expected to drive growth in the clinical use of blood perfusion and adsorption products [1] Group 3: Pricing Adjustment - Starting from September 2025, the company will adjust the price of its KHA130 blood perfusion device, which is specifically used for maintenance hemodialysis patients, as part of its commitment to social responsibility and patient care [1]